Recursion Pharmaceuticals (NasdaqGS:RXRX) reports positive clinical proof of concept for REC-4881 in familial adenomatous polyposis. The company records milestone progress across its collaborations ...

Researchers at the University of Tübingen have found via experimentation that crows are capable of understanding the concept of recursion. In their paper published in the journal Science Advances, ...

Recursion Pharmaceuticals, Inc. (RXRX) has been making great progress lately in being able to advance its pipeline. That's because it has been advancing two clinical candidates in phase 2 studies. It ...

Guidance extended from year-end 2027 to early 2028, with operating expense reduction targets reiterated and achieved at a greater scale (now 35% year-over-year, 10% below guidance). Strategic focus ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks on Jim Cramer’s radar recently. When a caller asked about the stock during the lightning round, Cramer stated: “I don’t know. It’s ...